Answers are grounded in this paper and cite their sources.
The global rise of antimicrobial resistance and the limited efficacy of current therapies against toxin-mediated pathology highlight the urgent need for innovative anti-infective strategies. In pneumococcal meningitis, a leading cause of mortality and long-term neurological sequelae, treatment is complicated not only by antibiotic-resistant Streptococcus pneumoniae (the pneumococcus) but also by the release of pneumolysin (Ply), a pore-forming toxin that drives neuronal damage and neuroinflammation. Here, we present the design and preclinical characterization of an endolysin-based dual-action fusion protein, using cpl-1 as a proof-of-concept scaffold, that combines bactericidal activity with toxin-neutralizing properties for infectious disease treatment. We engineered a chimeric protein by fusing a Mannose Receptor C-type 1 (MRC-1)-derived anti-Ply peptide to the N-terminus of the well-characterized pneumococcal endolysin cpl-1. The engineered endolysin demonstrated potent bactericidal activity against a broad panel of pneumococcal strains, including antibiotic-resistant and non-vaccine serotypes, producing an approximately 2-log10 CFU/mL reduction in human blood and approximately 60% reduction in turbidity in human cerebrospinal fluid. Importantly, the fusion protein could bind Ply reducing infection-associated neuronal cytotoxicity by more than 25% compared with cpl-1 in human neuronal cell models, addressing a key limitation of conventional bactericidal antibiotic therapies which can exacerbate toxin release. Mechanistically, incorporation of the MRC-1-derived peptide reduced toxin-induced damage, enabling simultaneous bacterial clearance and toxin neutralization. Furthermore, the fusion protein also demonstrated the ability to cross the blood-brain barrier in vivo; in a mouse model of penicillin-resistant invasive pneumococcal disease, the combination treatment, thanks to Ply-binding peptide (PBP)-cpl-1’s synergy with standard-of-care antibiotics, resulted in approximately 60% survival following a single dose and 65% survival following two doses, compared with 0% survival in untreated controls, together with delayed disease progression and reduced inflammatory responses in the brain and peripheral tissues. Collectively, our findings position engineered endolysins as a promising next-generation anti-infective strategy for the treatment of severe infections, particularly in anatomically protected sites such as the central nervous system, where current antibiotic therapies often show limited efficacy.
No takes yet. Share an insight, caveat, or question.
Elst et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: